期刊
FRONTIERS IN NEUROLOGY
卷 14, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fneur.2023.1172860
关键词
glioblastoma; liposomal honokiol; blood-brain barrier permeability; clinical trial; tumor progression
This article reports an efficient and safe response to three phases of treatment with liposomal honokiol in a patient with recurrent glioblastoma, suggesting its potential as a potent and safe anticancer agent.
Glioblastoma is the most common and aggressive primary tumor in the central nervous system. There is no standard of care for patients with recurrent GBM. Honokiol is a pleiotropic lignan and has the potential to be a potent and safe anticancer agent in human GBM when it is encapsulated by liposomes. We report an efficient and safe response to three phases of treatment with liposomal honokiol in a patient with recurrent glioblastoma.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据